| Literature DB >> 35815214 |
Dong-Qing Fei1, Hui-Hong Li1,2, Xiao-Han Chen1, Wen-Bo Cui1, Zong-Ping Zhang1, Xiao-Qing Zhan1, Mei-Jie Wang1, Feng-Ming Qi1, Zhan-Xin Zhang1, Er-Wei Li3,4.
Abstract
One novel diterpenoid lactone named caesalpinbondin A (1) that possesses an unprecedented tetracyclic ring system in which a 6/6/5-fused tricyclic ring and a 4,5-dimethyldihydrofuran-2(3H)-one were connected by a C-C single bond comprising a 5-(naphtho [2,3-b]furan-7-yl)dihydrofuran-2(3H)-one moiety was isolated from the seeds of Caesalpinia bonduc. Its chemical structure was established by extensive spectroscopic methods, and its absolute configuration was further determined by single-crystal X-ray diffraction analysis and electronic circular dichroism calculation. The biological evaluation suggested that compound 1 demonstrated potent anti-Alzheimer's disease (AD) bioactivity, which could delay paralysis of transgenic AD Caenorhabditis elegans. A possible biogenetic pathway of 1 was also proposed.Entities:
Keywords: Caenorhabditis elegans; Caesalpinia bonduc; Fabaceae; anti-Alzheimer’s disease bioactivity; caesalpinbondin A; diterpenoid
Year: 2022 PMID: 35815214 PMCID: PMC9263540 DOI: 10.3389/fchem.2022.911543
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.545
FIGURE 1Structure of caesalpinbondin A (1).
1H (600 MHz) and13C NMR (150 MHz) spectral data of compound 1 in CDCl3 (δ in ppm, J in Hz).
| No. |
|
| HMBC |
|---|---|---|---|
| 1 | 176.4, qC | — | — |
| 2 | 37.2, CH2 | 2.59, dd (18.0, 3.0) | 1, 3, 4, and 19 |
| — | 2.18, dd (18.0, 3.0) | — | |
| 3 | 39.4, CH | 3.08, m | 1, 2, 4, 5, 18, and 19 |
| 4 | 90.4, qC | — | — |
| 5 | 138.6, qC | — | — |
| 6 | 120.2, CH | 7.60, d (9.6) | 4, 5, 7, 8, and 10 |
| 7 | 122.7, CH | 8.00, d (9.6) | 5, 6, 8, 9, and 14 |
| 8 | 128.2, qC | — | — |
| 9 | 132.3, qC | — | — |
| 10 | 129.4, qC | — | — |
| 11 | 101.6, CH | 8.05, s | 8, 9, 10, 12, and 13 |
| 12 | 153.9, qC | — | — |
| 13 | 127.8, qC | — | — |
| 14 | 126.4, qC | — | — |
| 15 | 105.2, CH | 6.94, d (2.4) | 12, 13, 14, and 16 |
| 16 | 146.9, CH | 7.72, d (2.4) | 12, 13, and 15 |
| 17 | 15.6, CH3 | 2.87, s | 8, 13, and 14 |
| 18 | 23.5, CH3 | 1.82, s | 3, 4, and 5 |
| 19 | 16.4, CH3 | 1.32, d (7.2) | 2, 3, and 4 |
| 20 | 17.9, CH3 | 2.79, s | 5, 9, and 10 |
FIGURE 2Key 1H–1H COSY and HMBC correlations of caesalpinbondin A (1).
FIGURE 3Key NOESY correlations of caesalpinbondin A (1).
FIGURE 4ORTEP plot of the X-ray crystallographic structure for 1 (displacement ellipsoids were drawn at the 30% probability level).
FIGURE 5Experimental ECD spectrum of 1 and calculated ECD spectra for (3R, 4R)-1 and its enantiomer in MeOH.
SCHEME 1Plausible biosynthetic pathway for 1.
FIGURE 6Anti-Alzheimer’s disease (AD) activity of compound 1, positive control, and control. Worms were treated with 100 μM compound 1, 100 μM memantine was regarded as the positive control, and 0.1% DMSO was regarded as the control.